Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants

Documenti analoghi

• Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
  di: Irina Baltcheva, et al.
  Pubblicazione: (2026)
• Pharmacokinetics, pharmacodynamics and safety of oral formulation (CG‐750) of ivaltinostat, a histone deacetylase inhibitor, compared to IV formulation (CG‐745)
  di: Byungwook Kim, et al.
  Pubblicazione: (2024)
• Single‐dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: A first‐in‐human study
  di: C. Hu, et al.
  Pubblicazione: (2025)
• Pharmacokinetics and pharmacodynamics of intranasal insulin in a rat brain
  di: Jelena Osmanovic Barilar, et al.
  Pubblicazione: (2025)
• JAK–STAT inhibitory effect of IN‐115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine
  di: Jae‐Hun Ahn, et al.
  Pubblicazione: (2025)